Research into Blue Zones -- regions of the world where people tend to live longer -- shows that having a sense of purpose in life may help people live longer.

Now, new research from UC Davis shows that having a sense of purpose in life may have another benefit as people age: reducing the risk of dementia.

The new study, published in The American Journal of Geriatric Psychiatry, followed over 13,000 adults aged 45 and older for up to 15 years.

Researchers found that people who reported a higher sense of purpose in life were about 28% less likely to develop cognitive impairment -- including mild cognitive impairment and dementia.

The protective effect of having a purpose was seen across racial and ethnic groups. It also remained significant even after accounting for education, depression and the APOE4 gene, which is a known risk factor for Alzheimer's disease.

Purpose in life helps the brain stay resilient

"Our findings show that having a sense of purpose helps the brain stay resilient with age," said Aliza Wingo, senior author and professor in the UC Davis Department of Psychiatry and Behavioral Sciences. "Even for people with a genetic risk for Alzheimer's disease, sense of purpose was linked to a later onset and lower likelihood of developing dementia."

Participants were not specifically asked about the activities that gave their life purpose. Previous studies on aging, though, have found a wide rang of activities give older adults a sense of life purpose, sometimes referred to as "ikigai." These include:

  • Relationships: Caring for family, spending time with grandchildren or supporting a spouse or friend.
  • Work or volunteering: Continuing professional work, mentoring or contributing to community causes.
  • Spirituality or faith: Religious beliefs, spiritual practices or involvement in faith-based communities.
  • Personal goals: Pursuing hobbies, learning new skills or setting and achieving personal milestones.
  • Helping others: Acts of kindness, philanthropy, caregiving or advocacy work.

Purpose delays onset of cognitive decline

Researchers also found that people with higher purpose tended to experience cognitive decline later than those with lower purpose. On average, the delay in onset was very modest -- about 1.4 months over an eight-year period, after considering the effects of age, education, depressive symptoms, and genetic risk. However, it is meaningful when compared to current treatments.

"While medications like lecanemab and donanemab can modestly delay symptoms of cognitive impairment in Alzheimer's disease, they come with risks and costs," said Nicholas C. Howard, first author and public health researcher at UC Davis. "Purpose in life is free, safe and accessible. It's something people can build through relationships, goals and meaningful activities."

Methods and limitations of study

Participants in the study were part of the Health and Retirement Study, a nationally representative survey funded by the National Institute on Aging. All had normal cognitive health at the beginning of the study.

Researchers used a seven-item survey from the Ryff Measures of Psychological Well-being.Participants had six possible responses (from "strongly agree" to "strongly disagree") for statements such as: "I am an active person in carrying out the plans I set for myself" and "I have a sense of direction and purpose in my life." Their answers were scored and averaged to obtain a well-being number between 1 and 6, with higher values indicating a strong sense of purpose in life.

Their cognitive health was tracked using a telephone-based test every two years.

The researchers noted the study has many strengths, including the size of the population studied. However, a key limitation is that although there was an association, the study did not prove higher levels of purpose caused the lowered rates of dementia.

Findings support role of psychological well-being

Still, the findings support the idea that psychological well-being plays a key role in healthy aging, said Thomas Wingo, a co-author of the study and a professor and neurologist at UC Davis Health. Wingo hopes future studies will explore whether purpose-building interventions can help prevent dementia.

"What's exciting about this study is that people may be able to 'think' themselves into better health. Purpose in life is something we can nurture," he said. "It's never too early -- or too late -- to start thinking about what gives your life meaning."

Read more …Living with purpose may protect your brain from dementia

Could cocoa extract supplements rich in cocoa flavanols reduce inflammation and, in turn, prevent age-related chronic diseases? In a new study from the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), investigators from Mass General Brigham and their colleagues looked at changes in five age-related markers of inflammation among participants who received daily cocoa supplements over several years. They found that hsCRP -- an inflammatory marker that can signal increased risk of cardiovascular disease -- decreased in participants taking the cocoa extract supplement, suggesting its anti-inflammatory potential may help explain its heart-protective effects. Their results are published in Age and Ageing.

Nutritional interventions have become an increasingly attractive solution for slowing inflammatory aging, so called "inflammaging." Cocoa extract has been shown in previous, smaller studies to reduce inflammatory biomarkers, thanks to flavanols -- small, bioactive compounds found not only in the cocoa bean but also berries, grapes, tea, and other plant-based foods. To bridge the gap between these studies and humans, researchers launched the large-scale COSMOS trial, which examines the effects of cocoa extract on cardiovascular disease, and whether inflammaging may explain those effects.

"Our interest in cocoa extract and inflammaging started on the basis of cocoa-related reductions in cardiovascular disease," said corresponding author Howard Sesso, ScD, MPH, associate director of the Division of Preventive Medicine and associate epidemiologist at Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system. "We also appreciate the important overlap between healthy aging and cardiovascular health, where aging-related inflammation can harden arteries and lead to cardiovascular disease. Because of that, we wanted to see whether multi-year cocoa extract supplementation versus a placebo could modulate inflammaging -- and the data suggests it does."

Between 2014 and 2020, Brigham and Women's Hospital led the COSMOS trial, a large-scale, randomized, double-blind, placebo-controlled clinical trial with 21,442 participants over 60 years old, finding that cocoa extract supplementation decreased cardiovascular disease mortality by 27%.

In this new study, researchers collected and analyzed blood samples of 598 COSMOS participants to measure several inflammaging biomarkers: three pro-inflammatory proteins (hsCRP, IL-6, and TNF-α), one anti-inflammatory protein (IL-10), and one immune-mediating protein (IFN-γ). Comparing changes in these biomarkers measured at baseline, 1, and 2 years follow-up, hsCRP levels decreased by 8.4% each year compared with placebo, while the other biomarkers remained relatively consistent or increased modestly.

"Interestingly, we also observed an increase in interferon-γ, an immune-related cytokine, which opens new questions for future research," said senior author Yanbin Dong, MD/PhD, Director of the Georgia Prevention Institute (GPI) and cardiologist/population geneticist at the Medical College of Georgia/Augusta University. "While cocoa extract is not a replacement for a healthy lifestyle, these results are encouraging and highlight its potential role in modulatingi nflammation as we age.

The decrease in hsCRP may help explain the cardio-protective effects seen with cocoa extract supplement in the larger COSMOS trial, where participants experienced a reduction in cardiovascular disease death. Researchers said that changes in the other inflammaging markers, including a small reduction in IL-6 observed in female but not male participants, warrant additional study. The team will continue to evaluate the COSMOS trial to determine whether the cocoa -- and multivitamin -- regimens can curb more severe inflammaging, as well as other important aging-related health outcomes.

"This study calls for more attention to the advantage of plant-based foods for cardiovascular health, including cocoa products rich in flavanols," added Sesso. "It reinforces the importance of a diverse, colorful, plant-based diet -- especially in the context of inflammation."

Authorship: In addition to Sesso, Mass General Brigham authors include Sidong Li, Rikuta Hamaya, Allison Clar, Pamela M. Rist, and JoAnn E. Manson. In addition to Dong, Augusta University authors include Haidong Zhu and Ying Huang.

Disclosures: Manson and Sesso received investigator-initiated grants from Mars Edge, a segment of Mars Incorporated dedicated to nutrition research and products, for infrastructure support and donation of COSMOS study pills and packaging, and Pfizer Consumer Healthcare (now Haleon) for donation of COSMOS study pills and packaging during the conduct of the study. Sesso additionally reported receiving investigator-initiated grants from Pure Encapsulations, American Pistachio Growers, and Haleon, and honoraria and/or travel for lectures from the Council for Responsible Nutrition, BASF, Haleon, and NIH during the conduct of the study. No other authors reported any conflicts of interests for this study

Funding: This work is supported by the National Institutes of Health (HL157665). The COcoa Supplement and Multivitamin Outcomes Study (COSMOS) is supported by an investigator-initiated grant from Mars Edge, a segment of Mars dedicated to nutrition research and products, which included infrastructure support and the donation of study pills and packaging. Pfizer Consumer Healthcare (now Haleon) provided support through the partial provision of study pills and packaging. COSMOS is also supported in part by the National Institutes of Health (AG050657, AG071611, and EY025623). Neither company had a role in the trial design or conduct, data collection, data analysis, or manuscript preparation or review.

Read more …Cocoa supplements show surprising anti-aging potential

More Articles …